Key Takeaway: Rezolute, Inc. announced its participation in upcoming investor conferences, specifically the H.C. Wainwright 4th Annual BioConnect Investor Conference and the Jefferies Global Healthcare Conference, scheduled for June 2-4, 2026. The company, which focuses on treating hypoglycemia due to hyperinsulinism, will engage in fireside chats and one-on-one meetings with investors. This participation reflects Rezolute's commitment to enhancing its investor relations and showcasing its therapeutic advancements.
Price reaction · baseline $3.21 (2026-05-08 close) · 1 other RZLT headline(s) in the window, move may be shared
day 0 close
-1.2%
Conference Participation Details
Jefferies Global Healthcare Conference
Date: November 18, 2025
Time: 11:30 a.m. GMT / 6:30 a.m. ET
Location: London
Format: Fireside Chat
How to Access
Investors and the general public can listen to both sessions live at:
Archived versions will be available following the live events for a limited time.
Market Sentiment Analysis
POSITIVE FACTORS
Participation in prominent investor conferences may increase visibility.
Management's engagement with investors suggests confidence in the company.
Focus on a rare disease aligns with targeted therapeutic advancements.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+183%
120-day peak, hindsight
Typical move
5.3%
average across 2 past catalysts
Cash runway
~23 mo
Low dilution risk
Lead asset
Experimental: Group 1- RZ402
Phase 2 · Diabetic Macular Edema
Full Press Release Details
REDWOOD CITY, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by all forms of hyperinsulinism (HI), today announced that management will participate in the following investor conferences:
Management will be participating in fireside chats and one-on-one investor meetings throughout the conferences. Investors interested in scheduling a meeting with the Rezolute management team should contact their H.C. Wainwright and Jefferies representatives.
About Rezolute, Inc.
Rezolute is a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism (HI). The Company’s antibody therapy, ersodetug, is designed to treat all forms of HI and has been studied in clinical trials and used in real-world cases for the treatment of both congenital and tumor HI. For more information, visit www.rezolutebio.com.
Frequently Asked Questions
What is Rezolute, Inc. focused on?
Rezolute, Inc. specializes in treating hypoglycemia from all types of hyperinsulinism.
What therapy does Rezolute develop for hyperinsulinism?
Rezolute's antibody therapy, ersodetug, targets all forms of hyperinsulinism.
When will Rezolute participate in investor conferences?
Rezolute will participate in conferences from June 2-4, 2026.
How can investors meet with Rezolute's management?
Investors can schedule meetings by contacting their H.C. Wainwright and Jefferies reps.